More than 1,600 local students from 49 schools across east Kent have taken part in the region’s largest ever science jamboree.
The annual two-day event, held at Discovery Park in Sandwich, transformed the science and business park into a hub of exploration and hands-on learning, bringing together young people, businesses and universities to learn about the world of science, technology, engineering and mathematics (STEM).
Organised by STEM Hub at Canterbury Christ Church University, the jamboree delivers a range of exciting practical scientific experiments and activities for the students to…
LONDON, UK – June 16, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Cancer Research Horizons and is pleased to announce the placements of Heather Preston, Richard Wooster and Hans Bishop as Non-Executive Directors (NEDs) to its Board. Cancer Research Horizons is the innovation arm of Cancer Research UK. Its strategy focuses on working directly with researchers to help them maximize the impact of their work, providing funding, expertise and advice to translate…
Oxford, UK - 17 June 2026 - PrecisionLife has launched Biology Matters, a new podcast exploring how advances in biology, genomics, data science, and AI can help address one of healthcare's greatest challenges: chronic disease.The podcast's debut episode features hosts and PrecisionLife co-founders Steve and Rowan Gardner discussing the growing impact of chronic disease on patients, healthcare systems, and society, and the opportunities emerging from advances in precision medicine.Future episodes will feature leaders from across healthcare, biopharma, technology, research, and…
Amsbio has expanded its diverse range of recombinant and monoclonal antibodies to include over 10,000 new validated monospecific products in 15,000 formulations to support research in cancer, immunology, neuroscience, and signal transduction.
Every antibody in the new catalogue has been subject to rigorous validation technologies to confirm that they selectively recognize their intended targets across applications such as immunohistochemistry, western blot, flow cytometry and immunofluorescence. These recombinant and monoclonal antibodies also provide high sensitivity and minimal background…
Strengthens Board with experienced industry executive, specializing in strategic planning, organizational leadership and commercial execution
Cambridge, UK, 16 June 2026 – Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today announced the appointment of Bruce Eaton, PhD as Chairman of the Board, with immediate effect. The appointment aligns with the Company’s strategic growth objectives following recent senior leadership changes1, to drive global commercialization of the INDUCE-seq…
Cresset has released Flare V12, a new version of its computer-aided drug design (CADD) solution for the discovery, design and optimization of small molecules. Flare V12 is focussed on improving access to Free Energy Perturbation (FEP) in drug discovery.FEP is used to predict how strongly drug candidates bind to their targets, helping guide compound selection. However, despite its recognised accuracy, adoption has often been limited by computational cost, usability barriers and challenges in modeling complex chemical transformations.Flare V12 is designed to address these challenges.Reducing…
Here's some exciting news about the Cambridge Stock Exchange Project (CSEP).
The Cambridge Stock Exchange Project is creating a platform for accessing liquidity from the market inside high-density innovation ecosystems across the UK.
You can also learn more about the initiative on the Cambridge Stock Exchange Project website.
Sandwich, UK — 10 June 2026: Discovery Park, Kent’s science and innovation hub, has launched the seventh edition of its Discovery Spark accelerator programme, welcoming 12 startups to its campus in Sandwich.
The seventh cohort is themed around innovations in health, with startups selected based on the need for their innovation, the uniqueness of their solution, and the strength of their team. Throughout June, the selected founders will be attending specialist-led sessions in both Kent and London, focused on investor readiness, covering essential business topics from tax and finance,…
· Next-generation small molecule microtubule targeting agent, PMC-001, progressing towards Phase 1
· Comprehensive preclinical data package demonstrates differentiating oral activity and CNS penetration, unlocking treatment of primary and secondary brain cancers
· Dr Gabriel Fox appointed as Chief Medical Officer to lead clinical development
Cambridge, UK: PhoreMost Limited (“PhoreMost”), a biotech company focused on turning scientific breakthroughs into life-changing…
Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program to support advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease
Two-year programme expands Harness' neurodegenerative disease pipeline, leveraging proprietary MISBA® platform
Cambridge, UK, 9 June 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces it has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (…